Skip to content

Magnetic Resonance Post-contrast Vascular Hyperintensities at 3 T: a Sensitive Sign of Vascular Occlusion in Acute Ischaemic Stroke

Magnetic Resonance Post-contrast Vascular Hyperintensities at 3 T: a New Highly Sensitive Sign of Vascular Occlusion in Acute Ischaemic Stroke

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03971526
Enrollment
130
Registered
2019-06-03
Start date
2014-09-01
Completion date
2016-09-01
Last updated
2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischaemic Stroke

Keywords

Cerebrovascular disorders, Magnetic resonance imaging, Neuroimaging, Prognosis, Stroke

Brief summary

Magnetic resonance imaging (MRI) is the diagnostic cornerstone for precisely identifying acute ischaemic strokes and locating vascular occlusions. It was observed that a post-contrast three-dimensional turbo-spin-echo T1weighted sequence showed striking post-contrast vascular hyperintensities (PCVH) in ischaemic territories. The aim is to evaluate the prevalence and the meaning of this finding. This study included 130 consecutive patients admitted for acute ischaemic stroke with a 3-T MRI performed in the first 12 h of symptom onset from September 2014 through September 2016. Two neuroradiologists blinded to clinical data analysed the first MRI assessments.

Interventions

OTHERMRI images review

MR images were reviewed by one junior radiologist and one senior neuroradiologist, both blinded to clinical, therapeutic and follow-up data.

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild
Lead SponsorNETWORK

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 and older at onset of an acute ischaemic stroke * Availability of at least one pre-therapeutic MRI performed in our centre within 12 h of stroke onset, including a post-contrast 3D TSE T1-weighted sequence.

Exclusion criteria

* Patients with posterior fossa strokes * Patients with known intracranial vasculitis or MoyaMoya disease * Presence of severe MR imaging artefacts preventing correct interpretation

Design outcomes

Primary

MeasureTime frameDescription
overal survival7 yearsfrom the AR-PML diagnosis date to that of death or censored on 31 December 2015

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026